NanoCor Therapeutics, Incorporated released the results of a study indicating the company’s lead product, Carfostin, may improve cardiovascular health. The study, published in the Journal of the American College of Cardiology, showed a single dose correlated with up to a 25% improvement in heart function in swine. Carfostin is a gene therapy that delivers a calcium-regulating protein to damaged heart cells. If it is approved, it would be the first gene therapy used to treat late-stage congestive heart failure. Congestive heart failure affects approximately five million Americans, and it is one of the major causes of hospitalization for persons 65 and older. It is the final stage for many heart conditions, and it is typically diagnosed with a life expectancy of five years. Carfostin will next be tested on human subjects suffering advanced chronic heart failure. In the study, which will begin next year, patients will receive a single shot of one of four trial doses.